Assembly Biosciences, Inc.
Assembly Biosciences, Inc.
Your view on ASMB
Overview
What the company does, where it operates, and who runs it.
About Assembly Biosciences, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jason A. Okazaki
- Headquarters
- 331 Oyster Point Boulevard, South San Francisco, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Jason A. Okazaki
- Headquarters
- 331 Oyster Point Boulevard, South San Francisco, CA, US
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.
It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV.
The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection.
It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Assembly Biosciences, Inc., and the rating behind it. ASMB last traded at $29.80, 54.1× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Assembly Biosciences, Inc.. Starting points for Assembly Biosciences, Inc.: P/E 54.1, beta 1.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Assembly Biosciences, Inc.. Assembly Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Assembly Biosciences, Inc.. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Assembly Biosciences, Inc.. Assembly Biosciences, Inc. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Assembly Biosciences, Inc. valued side by side against its closest peers. Assembly Biosciences, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Assembly Biosciences, Inc., and how their positions are changing. At a $590.6M market value, institutional positions materially move Assembly Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Assembly Biosciences, Inc. executives and directors. Shares of Assembly Biosciences, Inc. have traded between $7.75 and $37.71 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Assembly Biosciences, Inc.. Assembly Biosciences, Inc. is a $590.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Assembly Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Assembly Biosciences, Inc.. Coverage tracks Assembly Biosciences, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.